Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | MLYCD | O95822 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.42 |
| ▸ | FAAH | O00519 | 8/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 5/20 | 0.40 |
| ▸ | CES2 | O00748 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045874 | 0.80 | MLYCD (0.57) | EPHX1MLYCDFAAHCES1CES2 | |
| SCHEMBL712857 | 0.80 | EPHX1 (0.50) | EPHX1MLYCDGPR84FAAHCES1 | |
| SCHEMBL28224073 | 0.79 | EPHX1 (0.53) | EPHX1MLYCDGPR84FAAHCES1 | |
| SCHEMBL18349792 | 0.77 | EPHX1 (0.47) | EPHX1MLYCDFAAHCES1CES2 | |
| SCHEMBL17972439 | 0.77 | EPHX1 (0.51) | EPHX1MLYCDGPR84FAAHCES1 | |
| SCHEMBL8179038 | 0.76 | NOD1 (0.54) | EPHX1GPR84MAPT | |
| SCHEMBL15942203 | 0.76 | EPHX1 (0.50) | EPHX1MLYCDFAAHCES1CES2 | |
| SCHEMBL8172600 | 0.76 | NOD1 (0.54) | EPHX1GPR84MAPT | |
| SCHEMBL15948722 | 0.76 | EPHX1 (0.50) | EPHX1MLYCDFAAHCES1CES2 | |
| SCHEMBL5270070 | 0.75 | EPHX1 (0.49) | EPHX1MLYCDGPR84FAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637492-B2 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo | GENE TOOLS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120035358-A1 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo | GENE TOOLS, LLC | 2012-02-09 | — | — | US | disclosed |
| US-7935816-B2 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo | GENE TOOLS, LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090171075-A1 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo | GENE TOOLS, LLC | 2009-07-02 | — | — | US | disclosed |
| WO-2009055027-A2 | MOLECULAR TRANSPORTER COMPOSITIONS COMPRISING DENDRIMERIC OLIGOGUANIDINE WITH A TRI-FUNCTIONAL CORE THAT FACILITATE DELIVERY INTO CELLS IN VIVO | LI YONG-FU (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171075-A1 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo | SLC18A1, SLC75A1, SLC2A1 | EPHX1 4017/4885MLYCD 2386/4885GPR84 128/4885 |
| US-20120035358-A1 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo | SLC29A2, SLC29A1, SLC2A9 | EPHX1 3620/4885MLYCD 2646/4885GPR84 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.